

BIOGEN IDEC INC  
Form 8-K  
February 19, 2004

Table of Contents

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 18, 2004

**Biogen Idec Inc.**

(Exact name of registrant as specified in its charter)

---

<b>Delaware</b> (State or other jurisdiction of incorporation)	<b>0-19311</b> (Commission File Number)	<b>33-0112644</b> (IRS Employer Identification No.)
<b>14 Cambridge Center, Cambridge, Massachusetts 02142</b> (Address of principal executive offices) (zip code)		

Registrant's telephone number, including area code: **(617) 679-2000**

**Not Applicable**

(Former name or former address, if changed since last report)

---

**TABLE OF CONTENTS**

ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

SIGNATURES

EXHIBIT INDEX

EX-99.1 PRESS RELEASE DATED FEBRUARY 18, 2004

---

**Table of Contents**

**ITEM 5. OTHER EVENTS AND REGULATION FD DISCLOSURE.**

On February 18, 2004, the Registrant and Elan Corporation, plc publicly disseminated a joint press release announcing that they intend to submit to the U.S. Food and Drug Administration an application for approval of ANTEGREN® (natalizumab) as a treatment for multiple sclerosis in mid-year 2004. The information contained in the press release is incorporated herein by reference and filed as Exhibit 99.1 hereto.

**ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.**

(c) Exhibits.

99.1 The Registrant's Press Release dated February 18, 2004.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 19, 2004

Biogen Idec Inc.  
(Registrant)

/s/ Anne Marie Cook

---

Anne Marie Cook  
Vice President, Chief Corporate Counsel

**Table of Contents**

EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Description</b>
99.1	The Registrant's Press Release dated February 18, 2004.